| RNA subtype | C1 (n = 13, 12.7%) Inflammatory | C2 (n = 45, 44.1%) EMT | C3 (n = 19, 18.6%) Stemness | C4 (n = 25, 24.5%) EGFR-dominant | Pa |
---|---|---|---|---|---|---|
Overall Survival b | HR (95% CI) | 0.68 (0.34-1.36) | 0.92 (0.60-1.42) | 6.77 (3.73-12.27) | 0.59 (0.35-0.97) | < 0.001 |
OS (month, median) | 22.8 | 23.0 | 4.2 | 36.7 | ||
Progression-free Survival b | HR (95% CI) | 0.79 (0.37-1.66) | 1.41 (0.87-2.28) | 2.76 (1.35-5.61) | 0.53 (0.31-0.91) | 0.020 |
PFS (month, median) | 3.90 | 2.20 | 2.15 | 5.50 | ||
Smoking | Pack (year, median) | 9.00 | 0.20 | 29.00 | 0.00 | 0.176 |
Sex | Male (n = 57, 55.9%) | 7 (6.9%) | 23 (22.6%) | 17 (16.7%) | 10 (9.8%) | 0.009 |
Female (n = 45, 44.1%) | 6 (5.9%) | 22 (21.6%) | 2 (2.0%) | 15 (14.7%) | ||
Cancer Type | SCLC (n = 6) | 0 (0.0%) | 2 (2.0%) | 4 (3.9%) | 0 (0.0%) | 0.015 |
NSCLC (n = 96) | 13 (12.8%) | 43 (42.2%) | 15 (14.7%) | 25 (24.5%) | ||
Sample timing | Baseline (n = 31) | 5 (4.9%) | 13 (12.7%) | 9 (8.8%) | 4 (3.9%) | 0.135 |
Post (n = 71) | 8 (7.8%) | 32 (31.4%) | 10 (9.8%) | 21 (20.6%) | ||
EGFR-TKI therapy group | Sample size (n = 27) | 2 (7.4%) | 15 (55.6%) | 0 (0.0%) | 10 (37.0%) | 0.038 |
BASELINE (n = 9) | 1 (3.7%) | 5 (18.5%) | 0 (0.0%) | 3 (11.1%) | ||
POST1 (n = 7) | 0 (0.0%) | 3 (11.1%) | 0 (0.0%) | 4 (14.8%) | ||
POST2 (n = 4) | 0 (0.0%) | 1 (3.7%) | 0 (0.0%) | 3 (11.1%) | ||
POST3 (n = 7) | 1 (3.7%) | 6 (22.2%) | 0 (0.0%) | 0 (0.0%) | ||
Target-seq | Sample size (n = 98) | 13 (13.3%) | 43 (43.9%) | 17 (17.3%) | 25 (25.5) |  |
TP53-mutation | Non-hotspot (n = 42) | 4 (4.1%) | 9 (9.2%) | 8 (8.2%) | 21 (21%) | < 0.001 |
Hotspot (n = 6) | 1 (1.0%) | 2 (2.0%) | 3 (3.1%) | 0 (0.0%) | ||
Wild-type (n = 50) | 8 (8.2%) | 32 (33%) | 6 (6.1%) | 4 (4.1%) | ||
EGFR-mutation | Target (n = 20) | 3 (3.1%) | 6 (6.1%) | 2 (2.0%) | 9 (9.2%) | 0.258 |
NOSaq (n = 2) | 0 (0.0%) | 2 (2.0%) | 0 (0.0%) | 0 (0.0%) | ||
T790Maq (n = 3) | 0 (0.0%) | 1 (1.0%) | 0 (0.0%) | 2 (2.0%) | ||
NOS (n = 5) | 0 (0.0%) | 3 (3.1%) | 2 (2.0%) | 0 (0.0%) | ||
Wild-type (n = 68) | 10 (10.2%) | 31 (31.6%) | 13 (13.3%) | 14 (14.3%) |